EUVIMEDEUVIMED entdecken
Open Access

PET-Based TheraP Eligibility and Outcomes of VISION-Eligible Patients with Metastatic Castration-Resistant Prostate Cancer Who Received 177 Lu-PSMA-617: Importance of 18 F-FDG–Avid Discordant Findings

Ridvan Arda Demirci, Alireza Ghodsi, Roman Gulati, Sanaz Behnia, Peter S Nelson, Heather H Cheng, Todd A Yezefski, Michael C Haffner, Jessica E Hawley, Robert B Montgomery, Evan Y Yu, Michael T Schweizer und 2 weitere

Journal of Nuclear Medicine · 2025-01 · 66 (1) · 47-53

DOI: 10.2967/jnumed.124.268167 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 14.11.2024. Verfasst von Ridvan Arda Demirci und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, University of Washington, Seattle, Washington. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Lutetium, Dipeptides, Fluorodeoxyglucose F18. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The VISION and TheraP trials introduced different PET-based criteria for patient selection for treatment with 177Lu-PSMA-617 (LuPSMA). TheraP used a higher prostate-specific membrane antigen (PSMA) uptake threshold than VISION and required 18F-FDG PET to exclude patients with discordant findings. Although the screen-failed patients had shorter overall survival (OS) than those treated with LuPSMA, it remains unclear whether their outcomes might have been modified if they had been exposed to LuPSMA. In this study, we evaluated associations between the TheraP eligibility criteria and subgroups and the treatment outcomes of patients who were deemed suitable and treated on the basis of VISION criteria.

Methods

Consecutive patients who were treated with LuPSMA and who underwent pretreatment PSMA and 18F-FDG PET were classified as TheraP-eligible (TheraP-E) and TheraP-ineligible (TheraP-I), the latter of which were subclassified as low PSMA or discordant. Odds ratios for an at least 50% decline in prostate-specific antigen (PSA50) were computed using logistic regression, and hazard ratios (HRs) for PSA progression-free survival (PSA-PFS) and OS were computed using Cox regressions. Multivariable analyses were adjusted for baseline imaging and clinical parameters.

Results

Of 75 patients, 31 (41%) were deemed TheraP-I; of those, 24 were subclassified as having discordant disease. TheraP-I patients had a lower PSA50 rate than that of TheraP-E patients (28% vs. 67%; odds ratio, 0.19; 95% CI, 0.06-0.52; P = 0.002) and a higher risk of PSA progression (HR, 2.0; 95% CI, 1.2-3.3; P = 0.007). OS in the TheraP-I group was numerically shorter than in the TheraP-E group, but the comparison was only marginally significant (10.4 mo vs. not reached; HR, 1.9; 95% CI, 1.0-3.7; P = 0.054). TheraP-I patients with low PSMA had no significantly different risk of death (P = 0.9) from that of TheraP-E patients, but those with discordant findings had higher risk of death (HR, 2.3; 95% CI, 1.1-4.6; P = 0.02). Discordant disease remained prognostic for OS after adjusting for baseline imaging and clinical parameters (HR, 3.0; 95% CI, 1.3-6.8; P = 0.01).

Conclusion

In VISION-eligible patients who were treated with LuPSMA, TheraP-I patients with discordant findings had lower PSA50, PSA-PFS, and OS. Our study suggests that the shorter OS of TheraP-I patients is mainly driven by the presence of discordant disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantLutetiumDipeptidesFluorodeoxyglucose F18Heterocyclic Compounds, 1-RingHumansMaleAgedTreatment OutcomeNeoplasm MetastasisPositron-Emission TomographyMiddle AgedProstate-Specific AntigenPatient SelectionAged, 80 and over

Stichwörter der Autor:innen

177Lu-PSMA18F-FDG PETPSMA PETeligibility criteria; discordant diseaseprostate cancer

Substanzen

LutetiumDipeptidesFluorodeoxyglucose F18Heterocyclic Compounds, 1-RingPluvictoProstate-Specific Antigen

Autor:innen und Institutionen

  • Department of Radiology, University of Washington, Seattle, Washington.
  • Division of Public Health Sciences, Fred Hutchinson Cancer Center, Seattle, Washington.
  • Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, Washington.
  • Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington.
  • Division of Human Biology, Fred Hutchinson Cancer Center, Seattle, Washington; and.
  • Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington.

Förderung

  • NCI NIH HHS

Zitieren

APA

Demirci, R. A., Ghodsi, A., Gulati, R., Behnia, S., Nelson, P. S., Cheng, H. H., Yezefski, T. A., Haffner, M. C., Hawley, J. E., Montgomery, R. B., Yu, E. Y., Schweizer, M. T., Chen, D. L., & Iravani, A. (2025). PET-Based TheraP Eligibility and Outcomes of VISION-Eligible Patients with Metastatic Castration-Resistant Prostate Cancer Who Received 177 Lu-PSMA-617: Importance of 18 F-FDG–Avid Discordant Findings. Journal of Nuclear Medicine, 66(1), 47-53. https://doi.org/10.2967/jnumed.124.268167

Vancouver

Demirci RA, Ghodsi A, Gulati R, Behnia S, Nelson PS, Cheng HH, et al. PET-Based TheraP Eligibility and Outcomes of VISION-Eligible Patients with Metastatic Castration-Resistant Prostate Cancer Who Received 177 Lu-PSMA-617: Importance of 18 F-FDG–Avid Discordant Findings. Journal of Nuclear Medicine. 2025;66(1):47-53. doi:10.2967/jnumed.124.268167

BibTeX
@article{Demirci2025,
  author = {Demirci, Ridvan Arda and Ghodsi, Alireza and Gulati, Roman and Behnia, Sanaz and Nelson, Peter S and Cheng, Heather H and Yezefski, Todd A and Haffner, Michael C and Hawley, Jessica E and Montgomery, Robert B and Yu, Evan Y and Schweizer, Michael T and Chen, Delphine L and Iravani, Amir},
  title = {PET-Based TheraP Eligibility and Outcomes of VISION-Eligible Patients with Metastatic Castration-Resistant Prostate Cancer Who Received 177 Lu-PSMA-617: Importance of 18 F-FDG–Avid Discordant Findings},
  journal = {Journal of Nuclear Medicine},
  year = {2025},
  volume = {66},
  number = {1},
  pages = {47--53},
  doi = {10.2967/jnumed.124.268167}
}
Kostenlos starten →